Peptide Sciences Shuts Down After FDA Crackdown on Gray-Market Vendors

Peptide Sciences, once the largest gray-market research peptide vendor in the United States, voluntarily shut down operations on March 6, 2026. The closure marks the most visible casualty of a sweeping federal enforcement campaign that has reshaped the peptide supply landscape over the past year.

What drove the closure

Three converging forces pushed Peptide Sciences out of business. First, coordinated enforcement from the FDA, Department of Justice, and FBI targeted companies supplying compounds like semaglutide, a GLP-1 receptor agonist used for diabetes and weight management, and tirzepatide, a dual GIP/GLP-1 receptor agonist, without pharmaceutical licensing. Warning letters issued in December 2024 to vendors including Prime Peptides, Xcel Peptides, SwissChems, and Summit Research signaled the beginning of an aggressive new posture.

Second, independent quality testing exposed significant problems. One of Peptide Sciences' products — retatrutide, a triple hormone receptor agonist under investigation for obesity — received a failing "E" rating from third-party analysis, undermining the company's quality claims.

Third, the collapse of the high-margin GLP-1 revenue stream, as branded manufacturers like Novo Nordisk and Eli Lilly stabilized supply, eroded the financial viability of gray-market operations.

Broader market implications

Peptide Sciences was not an isolated case. At least 10 major gray-market vendors have closed or ceased operations since late 2025. The trend reflects a fundamental shift: the era of loosely regulated "research-only" peptide sales in the U.S. appears to be ending.

The timing is notable given that the FDA is simultaneously moving to reclassify 14 previously restricted peptides back to Category 1 status, which would restore access through licensed compounding pharmacies. The message from regulators appears clear — peptide access should flow through legitimate pharmaceutical channels, not gray-market vendors operating under a "research use only" fiction.

What this means for patients

For the millions of Americans who relied on gray-market sources for peptides like BPC-157, a synthetic peptide derived from gastric juice studied for tissue repair, and AOD-9604, a modified fragment of human growth hormone researched for fat metabolism, the path forward runs through licensed compounding pharmacies and prescribing physicians. The FDA's expected reclassification could make this transition smoother — but only for peptides that clear the regulatory review.